AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (this "Amendment"), is dated as of November 5, 2025 (the "First Amendment Effective Date") and is entered into by and among ALTIMMUNE, INC., a Delaware corporation ("Company"), ALTIMMUNE, LLC, a Delaware limited liability company ("Altimmune Sub"), and SPITFIRE PHARMA, LLC, a Delaware limited liability company ("Spitfire", and, together with Company and Altimmune Sub, collectively "Borrower", and each a "Borro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-37798 Cartesian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 26-1622110 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 7495 New Horizon Way, Frederick, MD 21703 (Address of principal executive of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2025 | | | Name of each exchange on which | | --- | --- | --- | | Title of each class | Trading Symbol | registered | | Common Stock, $0.001 par value | AVTX | Nasdaq Capital Market | Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15( ...

Exhibit 99 OBU SHIFT @ Q3 2025 SHAREHOLDER LETTER INVESTORS.SHIFT4.COM Forward-Looking Statements This letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Shift4 Payments, Inc. ("we. "our," the "Company." o "Shift4") intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act ...

Exhibit 99.1 Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates Conference call and webcast today, November 6, 2025, at 8:00 a.m. ET (9:00 p.m. HKT) SHANGHAI & CAMBRIDGE, Mass., November 6, 2025 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2025, along with recent product highlights and corporate updates. "Zai Lab is entering the next phase of our growth, powered by the rapid advancement of our global pipeline and su ...

Warner Bros. Discovery Reports Third-Quarter 2025 Results | | | | Three Months Ended September 30, | | | | --- | --- | --- | --- | --- | --- | | | 2025 | | 2024 | % Change | | | $ in millions | | | | Reported | Ex-FX(") | | Distribution | S 4,702 | S | 4,920 | (4)% | (4)% | | Advertising | 1,407 | | 1,682 | (16)% | (17)% | | Content | 2,649 | | 2,721 | (3)% | (3)% | | Other | 287 | | 300 | (4)% | (7)% | | Total revenues | S 9,045 | ತಿ | 9,623 | (6)% | (6)% | | Net (loss) income available to Warner Bros. Dis ...

EXHIBIT 99.1 Priority Technology Holdings, Inc. Reports Third Quarter Financial Results Third Quarter Performance Driven by Strength of Unified Commerce Platform ALPHARETTA, GA - November 6, 2025 -- Priority Technology Holdings, Inc. (NASDAQ: PRTH) ("Priority" or the "Company"), the payments and banking solution that streamlines collecting, storing, lending, and sending money to unlock revenue opportunities, today announced its third quarter 2025 financial results including strong year-over-year diversified ...

Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results CAMBRIDGE, Mass. November 6, 2025 -- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today reported financial and business results for the third quarter ended September 30, 2025. "Entering the final months of 2025, we are focused on execution as we head toward a transformative year in 2026, with topline data expected from the pivotal Phase 3 LUCIDITY trial," said Joshua Cohen and Justin Klee, Co-CEOs of ...

HanesBrands Inc. Announces Third-Quarter 2025 Results WINSTON-SALEM, N.C. (November 6, 2025) – HanesBrands Inc. (NYSE: HBI), a global leader in everyday iconic apparel, today announced results for the third-quarter 2025. "Our top-line results for the quarter reflect an unanticipated late quarter shift in replenishment orders at one of our large U.S. retail partners; however, we saw underlying fundamentals of our business continue to improve in the quarter. Our inventory position at retail is strong. We're e ...